Clinical Trial Update: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating GSK3196165 vs placebo and tofacitinib in adults with moderately to severely active rheumatoid arthritis who failed csDMARDs/ bDMARDs; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• GSK3196165 (GSK3196165)
• Tofacitinib (tofacitinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: TERMINATED | Results posted: 2023-11-30